Comparative Pharmacology
Head-to-head clinical analysis: DEXAMETHASONE ACETATE versus ORTIKOS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXAMETHASONE ACETATE versus ORTIKOS.
DEXAMETHASONE ACETATE vs ORTIKOS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Agonist at glucocorticoid receptors, modulating gene expression to suppress inflammation, immune response, and adrenal function.
ORTIKOS (acalabrutinib) is a selective, irreversible inhibitor of Bruton tyrosine kinase (BTK). It forms a covalent bond with the active site cysteine residue (Cys481) in BTK, blocking downstream B-cell receptor signaling and inhibiting malignant B-cell proliferation and survival.
0.5-9 mg/day orally in divided doses every 6-12 hours; intravenously or intramuscularly as dexamethasone sodium phosphate; typical anti-inflammatory dose 0.75-9 mg/day. For cerebral edema: IV loading dose 10 mg, then 4 mg every 6 hours. For COVID-19: 6 mg IV or orally once daily for up to 10 days.
2 mg orally three times daily (total daily dose 6 mg).
None Documented
None Documented
Terminal elimination half-life: 3-5 hours in adults; slightly prolonged in neonates (approximately 12-24 hours) and patients with hepatic impairment. Clinical context: Duration of HPA axis suppression may exceed the presence of measurable drug; single dose typically suppresses cortisol for 24-36 hours.
Terminal half-life of 8 hours (range 6-10) in healthy adults; prolonged to 24 hours in severe renal impairment (CrCl <30 mL/min).
Renal (primarily as glucuronide and sulfate conjugates) and biliary/fecal (minor). Approximately 65-80% of a dose is excreted in urine within 24 hours as 20-beta-dihydrodexamethasone (inactive) and conjugated metabolites; about 10-15% appears in feces. Less than 5% is excreted unchanged.
Renal (70% unchanged), biliary/fecal (30% as metabolites)
Category D/X
Category C
Corticosteroid
Corticosteroid